Coherus Oncology, Inc. (CHRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.42+3.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CHRS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 50.9 | 42.2 | 267.0 | 1.2 | 211.0 | 326.6 | 475.8 | 356.1 | 0.0 | 1.6 | 190.1 | 30.0 | 31.1 |
| Total Revenues | — | — | — | — | — | — | — | — | 0.0 | 1.6 | 190.1 | 30.0 | 31.1 |
| Cost of Revenues | 15.8 | 13.8 | 117.6 | 0.4 | 70.1 | 57.6 | 37.7 | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | 92.6 | 100.6 | 167.7 | 120.5 | 198.5 | 169.7 | 139.1 | 137.0 | 94.2 | — | — | — | — |
| R&D Expenses | 101.2 | 108.9 | 93.3 | 96.1 | 199.4 | 363.1 | 142.8 | 94.2 | 110.2 | 162.4 | 254.4 | 213.1 | 78.2 |
| Operating Income | (158.7) | (181.1) | (111.7) | (215.8) | (256.9) | (263.9) | 156.3 | 107.8 | (204.4) | (232.1) | (115.9) | (219.1) | (64.7) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | 9.1 | 9.0 | 27.2 | 11.1 | 32.5 | 23.0 | 21.2 | 17.6 | 9.7 | 9.6 | 8.0 | 0.0 | 3.9 |
| Interest & Investment Income | — | 7.0 | 4.5 | 2.8 | 1.9 | 1.4 | 0.6 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | 8.3 | 30.6 | 21.6 | 20.6 | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (161.1) | (183.1) | 28.5 | (222.1) | (291.8) | (287.1) | 135.7 | 92.8 | — | — | — | — | — |
| Income Tax Expense | — | — | — | (0.4) | 0.0 | 0.0 | 3.5 | 2.9 | 0.0 | 0.0 | 0.0 | — | — |
| Earnings from Continuing Operations | (161.1) | (183.1) | — | (221.8) | — | — | — | — | — | — | — | — | — |
| Net Income | |||||||||||||
| Minority Interest | — | — | — | — | — | — | — | 0.0 | (0.1) | (0.1) | (0.5) | (0.7) | (0.0) |
| Net Income | (132.1) | 168.0 | 28.5 | (237.9) | (291.8) | (287.1) | 132.2 | 89.8 | (209.3) | (238.2) | (127.3) | (223.3) | (87.1) |
| Per Share | |||||||||||||
| Basic EPS | (0.85) | 1.43 | 0.25 | (2.53) | (3.76) | (3.81) | 1.85 | 1.29 | — | — | — | — | — |
| Diluted EPS | (0.85) | 1.43 | 0.25 | (2.53) | (3.76) | (3.81) | 1.62 | 1.23 | — | — | — | — | — |
| Revenue per Share | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 154.8 | 117.1 | 114.6 | 94.2 | 77.6 | 75.4 | 71.4 | 69.7 | — | — | — | 37.1 | 8.5 |
| Diluted Weighted Avg Shares | 154.8 | 117.1 | 114.8 | 94.2 | 77.6 | 75.4 | 83.5 | 73.2 | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (177.2) | (106.4) | (212.0) | (253.2) | (260.4) | 159.2 | 111.0 | (201.2) | (228.7) | (112.9) | (217.2) | (64.0) |
| EBIT | (158.7) | (181.1) | (111.7) | (215.8) | (256.9) | (263.9) | 156.3 | 107.8 | (204.4) | (232.1) | (115.9) | (219.1) | (64.7) |
| Effective Tax Rate | — | — | — | 0.2% | 0.0% | 0.0% | 2.6% | 3.2% | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.